Editor John Hughman and guests discuss Brexit, corporate fines, ageing & more

Investors' Chronicle has supported private investors in the UK for over 160 years by highlighting rewarding investment opportunities.

Investors' Chronicle is a service by the Financial Times.

Hosted on Acast. See acast.com/privacy for more information.

With money rotating out of bonds and into equity markets, value investing is back in vogue. But what constitutes value? How can investors spot it? And what are the common pitfalls?In this special podcast, tips editor Algy Hall and deputy companies editor Mark Robinson walk through the key measures and metrics beloved of value investors, with a little help from two of the UK's top fund managers.Produced by Graeme Davies, Dominic Toms and Alex Newman.

Investors' Chronicle has supported private investors in the UK for over 160 years by highlighting rewarding investment opportunities.

Investors' Chronicle is a service by the Financial Times.

Hosted on Acast. See acast.com/privacy for more information.

Aviva faces regulatory changes, such as the 2015 pensions freedom reforms. It has been on the M&A trail, through its takeover of rival Friends Life. And now, it has set its sights on disrupting the Asian life market.It's also been a decent long-term investment since a strategic shift in 2012. Cash generation is up, debt is down, and non-core businesses are gone. Financial services writer Emma Powell spoke to Aviva's head of UK insurance Andy Briggs about the how investors can value life assurance in a diversifying business. Produced by Dominic Toms.

Investors' Chronicle has supported private investors in the UK for over 160 years by highlighting rewarding investment opportunities.

Investors' Chronicle is a service by the Financial Times.

Hosted on Acast. See acast.com/privacy for more information.

In this week's show the team consider how to pick a good fund manager, and highlight some examples. They also look at the risks and rewards of the Lifetime Isa, which is set to launch next month. They are joined by Darius McDermott, managing director at Chelsea Financial Services.

Investors' Chronicle has supported private investors in the UK for over 160 years by highlighting rewarding investment opportunities.

Investors' Chronicle is a service by the Financial Times.

Hosted on Acast. See acast.com/privacy for more information.

Editor John Hughman and guests discuss Sky/Fox, drug developments and cognitive biases in our weekly podcast

Investors' Chronicle has supported private investors in the UK for over 160 years by highlighting rewarding investment opportunities.

Investors' Chronicle is a service by the Financial Times.

Hosted on Acast. See acast.com/privacy for more information.

Summit Therapeutics is a small-cap biotech company with two drugs in clinical trials at either end of the new drugs space: a low risk, lower reward antibiotic and a high risk, higher reward Duchenne Muscular Dystrophy cure. Does this make it an ideal biotech investment? Megan Boxall investigates.

Investors' Chronicle has supported private investors in the UK for over 160 years by highlighting rewarding investment opportunities.

Investors' Chronicle is a service by the Financial Times.

Hosted on Acast. See acast.com/privacy for more information.

In this week's show James Baxter, partner at Tideway Wealth, joins the team to look at which investment trusts have proved to be the most reliable dividend payers over the years. They also consider some changes to the requirements for UK Equity Income sector funds and highlight a tax allowance that is soon to disappear.

Investors' Chronicle has supported private investors in the UK for over 160 years by highlighting rewarding investment opportunities.

Investors' Chronicle is a service by the Financial Times.

Hosted on Acast. See acast.com/privacy for more information.

IC editor John Hughman, news editor Emma Powell and companies editor Ian Smith discuss the week's big news, including the surge in M&A and continuing regulatory ructions in the telecoms and media industry.

Investors' Chronicle has supported private investors in the UK for over 160 years by highlighting rewarding investment opportunities.

Investors' Chronicle is a service by the Financial Times.

Hosted on Acast. See acast.com/privacy for more information.

BT's (BT.A) chief executive, Gavin Patterson, is not the only FTSE 100 boss to have announced a profit warning since the start of 2017. Several high profile companies have been forced to restate guidance since the start of the year. So is this a side effect of the current macroeconomic instability or do investors need to be wary of company structural issues which pre-date Brexit-related turmoil? And do these profit warnings present buying opportunities or should investors jump ship from companies in turmoil?In this podcast Alan Hudson, partner at EY, and the IC's companies editor, Ian Smith, join Megan Boxall to discuss why so many companies have had such a rough start to 2017.Introduction audio is the copyright of Reuters and BT.

Investors' Chronicle has supported private investors in the UK for over 160 years by highlighting rewarding investment opportunities.

Investors' Chronicle is a service by the Financial Times.

Hosted on Acast. See acast.com/privacy for more information.

The importance of nutrition in sporting success has created a big market for elite sports supplements. But is the market for amateur athletes big enough to support growth at Aim-listed group Science in Sport (SIS)? Megan Boxall talks to the group's chief executive, Stephen Moon.

Investors' Chronicle has supported private investors in the UK for over 160 years by highlighting rewarding investment opportunities.

Investors' Chronicle is a service by the Financial Times.

Hosted on Acast. See acast.com/privacy for more information.